Application of Opaganib in preparation of leukemia related products

By using Opaganib as a Sphk2 inhibitor, Sphk2 activity was inhibited, and the therapeutic drugs for leukemia were developed, which solved the problem of poor effect of existing leukemia treatment, significantly reduced the chimeric rate of leukemia cells and spleen congestion, and improved survival rate. Effective prevention and treatment of leukemia.

CN118924746APending Publication Date: 2024-11-12SUN YAT SEN UNIV
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410988151.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing treatment methods for leukemia are of average effect, and no effective Sphk2 inhibitor has been used for the treatment of leukemia.

Method used

Using Opaganib (ABC294640) as a selective Sphk2 inhibitor, drugs for the prevention and treatment of leukemia are developed by inhibiting Sphk2 activity, combined with pharmaceutically acceptable excipients, including oral, intravenous, intraperitoneal and cutaneous administration routes. Intradermal/subcutaneous administration.

Benefits of technology

It significantly reduced the chimeric rate of leukemia cells and spleen congestion, improved the weight and bone marrow hematopoiesis of mice, extended the survival rate, reduced the transient mortality rate, and showed effective prevention and treatment effects on leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924746A_ABST
    Figure CN118924746A_ABST
Patent Text Reader

Abstract

The invention relates to an application of Opaganib in preparation of leukemia related products, belongs to the field of biological medicines, and particularly relates to an application of Opaganib in preparation of drugs for treating leukemia. The Opaganib can reduce the number of leukemia cells in peripheral blood and bone marrow, effectively reduce extravasated blood and swelling of the spleen of a mouse with leukemia, prolong the survival time of the mouse with leukemia, and provide a new strategy for prevention and treatment of leukemia.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to the use of Opaganib in preparing leukemia-related products. Background Art

[0002] Acute myeloid leukemia (AML) or acute non-lymphocytic leukemia (ANLL) includes all acute leukemias of non-lymphocyte origin. It is a type of disease caused by mutations in the karyotype of pluripotent stem cells or slightly differentiated precursor cells. It is a clonal malignant disease of the hematopoietic system. Currently, it requires chemotherapy, radiotherapy, stem cell transplantation and other treatment methods, but the treatment effect is general.

[0003] Sphingolipids are common components of the nuclear membrane of eukaryotic organisms. Their metabolites, ceramide (Cer), sphingosine (Sph) and sphingosine-1-phosphate (S1P), maintain a dynamic balance in the cell and have important physiological functions, including regulating cell growth and survival. S1P is produced by the phosphorylation of Sph, and the key rate-limiting enzymes of this reaction are type 1 and type 2 sphingosine kinases (Sphk). Sphingosine kinase-2 (Sphk2) is a key rate-limiting enzyme and intracellular signal transduction enzyme that maintains the balance of intracellular sphingolipids, and is involved in regulating a variety of physiological functions such as apoptosis, inflammation and metabolism.

[0004] Sphk2 inhibitors are compounds that can inhibit the activity of Sphk2, and by inhibiting the activity of Sphk2, they have a positive effect on the treatment of related diseases. However, it should be noted that Sphk2 inhibitors are currently still in the research and development stage, and their clinical application requires further research and verification.

[0005] ABC294640 (Opaganib), 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl) amide, is an aromatic adamantane compound. As a new chemical entity, ABC294640 is a proprietary, first-in-class oral Sphk2 selective inhibitor with anti-tumor, anti-inflammatory and antiviral activities targeting a variety of tumor, viral, inflammatory and intestinal indications. By inhibiting Sphk2, ABC294640 can affect multiple cellular pathways associated with cancer cell growth, viral replication and pathological inflammation. ABC294640 has excellent oral bioavailability and shows a plasma elimination half-life of 4.5h in mice. Treatment of mice with ABC294640 induced a transient, slight decrease in the hematocrit of mice, which returned to normal after 28 days; no other hematological parameters or histopathological changes were found. Sphk2 can effectively regulate the metabolic level of hematopoietic cells and improve normal hematopoietic capacity.

[0006] There are currently no reports on the use of ABC294640 in the treatment of leukemia. Summary of the invention

[0007] In order to solve the above problems, the present invention provides the use of Opaganib in preparing a product for preventing and / or treating leukemia, providing a new idea for the prevention and treatment of leukemia.

[0008] In one aspect, the present invention provides the use of Opaganib in the preparation of a product for preventing and / or treating leukemia, wherein the structural formula of the Opaganib is:

[0009]

[0010] Specifically, the leukemia is acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and / or chronic myeloid leukemia.

[0011] Preferably, the leukemia is acute myeloid leukemia.

[0012] Specifically, the products are medicines, pharmaceutical raw materials, and industrial raw materials.

[0013] In another aspect, the present invention provides a drug for preventing and / or treating leukemia, the drug comprising:

[0014] (1) Opaganib, structural formula:

[0015]

[0016] (2) Pharmaceutically acceptable excipients.

[0017] Specifically, the pharmaceutically acceptable excipients can be selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

[0018] Specifically, the leukemia is acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and / or chronic myeloid leukemia.

[0019] More specifically, the acute lymphoblastic leukemia is characterized by abnormal proliferation and aggregation of immature lymphocytes in the bone marrow and lymphoid tissues, and is more common in children;

[0020] The acute myeloid leukemia is also called acute non-lymphocytic leukemia, which is a leukemia in which abnormal clones of hematopoietic cells other than lymphocytes occur, such as granulocytic leukemia, erythroleukemia, and megakaryocytic leukemia. It is the most common type of acute leukemia in adult patients.

[0021] The chronic lymphocytic leukemia is characterized by the accumulation of mature B lymphocytes in peripheral blood, bone marrow, spleen and lymph nodes, and mainly occurs in middle-aged and elderly people;

[0022] The chronic myeloid leukemia is characterized by abnormal increase of peripheral blood leukocytes, increase of neutrophil late myelocytes and mature granulocytes, and eosinophils.

[0023] Preferably, the leukemia is acute myeloid leukemia (AML).

[0024] Specifically, the drug may also include one or more other drugs for treating leukemia.

[0025] More specifically, the one or more other drugs for treating leukemia can be selected from anti-tumor drugs and / or targeted drugs.

[0026] Specifically, the dosage of Opaganib can be 50-100 mg / kg.

[0027] More specifically, the dosage of Opaganib is 50 mg / kg.

[0028] Specifically, the administration routes of the drug include, but are not limited to: oral administration, intravenous injection, intraperitoneal injection, intradermal administration and / or subcutaneous administration.

[0029] Preferably, the drug is administered by intraperitoneal injection.

[0030] The technical effects achieved by the present invention are:

[0031] (1) The chimerism rate of GFP+ cells in the ABC294640-treated group was lower than that in the control group.

[0032] (2) The body weight of mice in the ABC294640-treated group was greater than that in the control group.

[0033] (3) The degree of spleen congestion and swelling in the ABC294640-treated group was smaller than that in the control group.

[0034] (4) The spleen weight of mice in the ABC294640-treated group was significantly lower than that in the control group.

[0035] (5) The chimerism rate of bone marrow GFP+ cells in the ABC294640-treated group was significantly lower than that in the control group.

[0036] (6) The apoptosis rate of bone marrow GFP+ cells in the ABC294640-treated group was significantly higher than that in the control group.

[0037] (7) The survival rate of mice in the control group showed a nearly linear downward trend, with a high instantaneous mortality rate; while the survival rate of the ABC294640-treated group tended to be stable in the early stage, and gradually decreased in the later stage, with an instantaneous mortality rate lower than that of the control group. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 It is the result graph of Example 1, wherein A is the chimerism rate of GFP+ cells in the control group and the ABC294640-administered group; wherein B is the weight of mice in the control group and the ABC294640-administered group; wherein C is the spleen congestion and swelling of mice in the control group and the ABC294640-administered group; wherein D is the spleen weight of mice in the control group and the ABC294640-administered group; wherein E is the chimerism rate of GFP+ cells in the bone marrow of the control group and the ABC294640-administered group; wherein F is the apoptosis rate of GFP+ cells in the bone marrow of the control group and the ABC294640-administered group; wherein G is the survival curve of mice in the control group and the ABC294640-administered group.

[0039] Figure 2 The inhibitory effects of ABC294640 on different cell lines.

[0040] Figure 3 The inhibitory effects of different Sphk2 inhibitors on leukemia cancer cells. DETAILED DESCRIPTION

[0041] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0042] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0043] As used herein, the term "comprises" or "comprising" means "including but not limited to". The term is intended to be open-ended to specify the presence of any stated features, elements, integers, steps, or components, but does not exclude the presence or addition of one or more other features, elements, integers, steps, components, or groups thereof. Thus, the term "comprising" encompasses the more restrictive terms "consisting of" and "consisting essentially of". In one embodiment, the term "comprising" as used throughout the application, especially in the claims, may be replaced by the term "consisting of".

[0044] As used herein, the terms "optional," "either," "any," or "either" mean that the subsequently described event or circumstance may but need not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not occur.

[0045] As used herein, the term "about" refers to a range of ±20% of the value that follows. In some embodiments, the term "about" refers to a range of ±10% of the value that follows. In some embodiments, the term "about" refers to a range of ±5% of the value that follows.

[0046] The term "and / or" used herein should be understood to mean any one of the optional items or a combination of any two or more of the optional items.

[0047] Reagents and cell lines used in the present invention:

[0048] ABC294640(TargetMol,Catalog No.T6750,CAS 915385-81-8);

[0049] DMSO (Sigma-Aldrich, Catalog No. D2650, CAS 67-68-5);

[0050] PEG300 (Sigma-Aldrich, CAS25322-68-3);

[0051] SK1-178 (Targetmol, Catalog No. T9014, CAS1259484-97-3);

[0052] K145 (Targetmol, Catalog No. TQ0138, CAS1449240-68-9);

[0053] K562 (Procell, Catalog No. CL-0130);

[0054] HL60 (Procell, Catalog No. CL-0110);

[0055] MM1S (Procell, Catalog No. CL-0614);

[0056] NCI-H929 (Procell, Catalog No. CL-0509).

[0057] Example 1

[0058] 1.1 In vivo experimental animal model

[0059] (1) Control group AML leukemia mouse model: SPF grade MA9 (MLL-AF9)-GFPC57BL / 6J mice were obtained from the Experimental Animal Center of Zhongshan Medical College, Sun Yat-sen University. It is believed that AML is present when the GFP+ cell chimerism rate is greater than 10%.

[0060] (2) ABC294640 administration group mouse model: ABC294640 was dissolved in DMSO and diluted to the working concentration with saline:PEG300=1:1. The administration concentration was 50 mg / kg and intraperitoneally injected into AML leukemia mice 3 times a week for 3 weeks.

[0061] 1.2 Experimental Procedure

[0062] (1) The chimerism rate (%) of peripheral blood GFP+ cells was measured every 2 days starting from the 18th day until the 34th day;

[0063] (2) The body weight (g) of mice in the treatment group and the control group was measured 3 weeks after administration;

[0064] (3) After 34 days, the spleens of mice were removed and their gross lesions were observed;

[0065] (4) Weigh the spleen weights of the two groups;

[0066] (5) After 34 days, the bone marrow of mice was harvested and the chimerism rate of bone marrow GFP+ cells was detected;

[0067] (6) After 34 days, the bone marrow of mice was harvested and the apoptosis rate of GFP+ cells was detected;

[0068] (7) After administration, the survival of mice in the ABC294640-treated group and the control group was observed, and a survival curve was drawn.

[0069] 1.3 Experimental Results

[0070] Figure 1 A in the figure shows that the chimerism rate of GFP+ cells in the ABC294640-administered group was lower than that in the control group; Figure 1 B in the figure shows that the body weight of mice in the ABC294640-administered group was greater than that in the control group; Figure 1 C in the figure shows that the mice in the control group showed congestion and enlargement of the spleen, while the congestion and enlargement of the spleen in the mice in the ABC294640 administration group were smaller than those in the control group; Figure 1 D in the figure shows that the spleen weight of mice in the ABC294640-administered group was significantly lower than that in the control group; Figure 1 E in the figure shows that the chimerism rate of bone marrow GFP+ cells in the ABC294640-administered group was significantly lower than that in the control group; Figure 1 F in the figure shows that the apoptosis rate of bone marrow GFP+ cells in the ABC294640-administered group was significantly higher than that in the control group; Figure 1 The G in the figure shows that the survival rate of mice in the control group showed an almost linear downward trend, with a high instantaneous mortality rate; while the survival rate of the ABC294640-treated group tended to be stable in the early stage, and gradually decreased in the later stage, with an instantaneous mortality rate lower than that of the control group.

[0071] Example 2

[0072] In this example, commonly used leukemia cell lines K562 and HL60 were used to conduct experiments at the cytological level.

[0073] The experimental process is as follows:

[0074] Preparation of ABC294640: Take 5 mg of ABC294640 powder and add 657.7 μL of DMSO to make a 20 mM concentrate. Dilute 1000 times before use, and the working concentration is 20 μM.

[0075] Leukemia cell lines HL60 and K562, myeloma cell lines MM1S and NCI-H929 were seeded in 96-well plates, 30,000 cells per well, and 5 wells were repeated for each treatment. The drug group was given ABC294640 (20 μM), and the control group was given an equal amount of PBS. After 48h and 72h of culture, the cells were collected and stained with 7AAD to detect the apoptosis rate of the cells.

[0076] Comparative Example

[0077] The comparative example 2 is set as follows:

[0078] Comparative Example Differences from Example 2 Comparative Example 1 Replace ABC294640 with an equal amount of SK1-178 Comparative Example 2 Replace ABC294640 with an equal amount of K145 Comparative Example 3 Replaced the commonly used leukemia cell lines with the commonly used myeloma cell lines MM1S and NCI-H929

[0079] Preparation of SK1-178: 5 mg of SK1-178 powder was added to 657.7 μL of DMSO to make a 20 mM concentrate. Dilute 1000 times when using, and the working concentration is 20 μM;

[0080] Preparation of K145: Take 5 mg of K145 powder and add 657.7 μL of DMSO to make a 20 mM concentrate. Dilute 1000 times before use, and the working concentration is 20 μM.

[0081] Performance data:

[0082] Depend on Figure 2 It can be seen that ABC294640 can effectively inhibit the activity of leukemia cancer cells, but has no inhibitory effect on the activity of myeloma cells.

[0083] Depend on Figure 3 It can be seen that the inhibitory effects of Sphk2 inhibitors SK1-178 and K145 on the activity of leukemia cancer cells are significantly weaker than ABC294640. The results show that not all non-lipid competitive inhibitors of Sphk2 can achieve good effects in leukemia.

Claims

1. Use of Opaganib in the preparation of products for the prevention and / or treatment of leukemia, It is characterized in that The structural formula of Opaganib is:

2. The use according to claim 1, characterized in that the leukemia is acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and / or chronic myeloid leukemia.

3. The use according to claim 2, characterized in that the leukemia is acute myeloid leukemia.

4. The use according to any one of claims 1 to 3, characterized in that the product is a drug, a pharmaceutical raw material, or an industrial raw material.

5. A drug for preventing and / or treating leukemia, It is characterized in that The medicine comprises: (1) Opaganib, structural formula: (2) Pharmaceutically acceptable excipients.

6. The drug according to claim 5, characterized in that the pharmaceutically acceptable excipient is selected from one or a combination of two or more of wetting agents, emulsifiers, preservatives, antioxidants, buffers, excipients, diluents, lubricants, antibacterial agents, suspending agents, suspending aids, solubilizers, thickeners, stabilizers, sweeteners and flavors.

7. The medicine according to claim 5, characterized in that the leukemia is acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia and / or chronic myeloid leukemia.

8. The medicine according to claim 7, characterized in that the leukemia is acute myeloid leukemia.

9. The drug according to any one of claims 5 to 8, characterized in that the drug can also include one or more other drugs for treating leukemia.

10. The drug according to claim 9, characterized in that the one or more other drugs for treating leukemia are selected from anti-tumor drugs and / or targeted drugs.

11. The drug according to claim 5, characterized in that the dosage of Opaganib is 50-100 mg / kg.

12. The drug according to claim 5, characterized in that the drug is administered orally, intravenously, intraperitoneally, intradermally and / or subcutaneously.

Citation Information

Cited By

  • Application of Opaganib in preparation of anti-aging product

    CN119700758A